Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients
Background: Hepatocellular carcinoma [HCC] is one of the leading causes of cancer-related deaths worldwide. A major problem with HCC surveillance is the lack of reliable biomarkers. Serum transthyretin [TTR] may be a sensitive marker for the diagnosis of patients with liver cell damage, liver cirrho...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Egyptian knowledge bank
2020-04-01
|
Series: | International Journal of Medical Arts |
Subjects: | |
Online Access: | https://ijma.journals.ekb.eg/article_82380_37df342f1483d981733ec70d834c8af1.pdf |
id |
doaj-709c6afa507b4ed8be2a6b9fd04fca2e |
---|---|
record_format |
Article |
spelling |
doaj-709c6afa507b4ed8be2a6b9fd04fca2e2021-01-15T16:33:21ZengEgyptian knowledge bankInternational Journal of Medical Arts2636-41742682-37802020-04-012241241910.21608/ijma.2020.23373.109482380Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic PatientsMagda Ibrahim0Fathiya El-Raey1Naglaa Fathy2Kadrey El-Bakrey3Department of Physiology (Zoology), Faculty of Science, Damietta University, EgyptDepartment of Hepatogastroenterology and Infectious Diseases, Damietta Faculty of Medicine, Al-Azhar University, EgyptDepartment of Zoology (Physiology), Faculty of Scicene, Damietta University, EgyptDepartment of Zoology (physiology) Faculty of science, Damietta University, EgyptBackground: Hepatocellular carcinoma [HCC] is one of the leading causes of cancer-related deaths worldwide. A major problem with HCC surveillance is the lack of reliable biomarkers. Serum transthyretin [TTR] may be a sensitive marker for the diagnosis of patients with liver cell damage, liver cirrhosis or hepatocellular carcinoma. Aim of the work: This study aimed to evaluate the potentiality of serum transthyretin [TTR] as a novel biomarker for detection of HCC in cirrhotic patients. Patients and Methods:This Current study was conducted on 70 patients with chronic liver disease. Also, 20 healthy person matched for age and sex were included as a control group. Patients were classified into 2 groups [30 cirrhotic patients with newly diagnosed HCC & 40 cirrhotic patients without HCC]. Serum TTR levels were measured using enzyme linked immunosorbent assay technique. Results: Serum levels of TTR were significantly much lower in HCC patients when compared to cirrhotic patients without HCC or control group [p<0.0001]. Significant decrease of serum TTR in HCC patients, with portal vein invasion or nodal invasion than in HCC without vascular or nodal invasion. The diagnostic accuracy of TTR was higher than that of AFP regarding sensitivity [83.3%] and negative predictive value [81.4%] in diagnosis of HCC. Conclusion: detection of lower level of TTR alone or in combination with other validated markers may be potentially informative biomarker for detection of HCC among cirrhotic patients at early noninvasive stage where curative treatment can be applied.https://ijma.journals.ekb.eg/article_82380_37df342f1483d981733ec70d834c8af1.pdfttransthyretincirrhosishepatocellular carcinomaalpha-fetoproteinnoninvasive |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Magda Ibrahim Fathiya El-Raey Naglaa Fathy Kadrey El-Bakrey |
spellingShingle |
Magda Ibrahim Fathiya El-Raey Naglaa Fathy Kadrey El-Bakrey Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients International Journal of Medical Arts ttransthyretin cirrhosis hepatocellular carcinoma alpha-fetoprotein noninvasive |
author_facet |
Magda Ibrahim Fathiya El-Raey Naglaa Fathy Kadrey El-Bakrey |
author_sort |
Magda Ibrahim |
title |
Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients |
title_short |
Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients |
title_full |
Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients |
title_fullStr |
Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients |
title_full_unstemmed |
Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients |
title_sort |
transthyretin as a novel biomarker for diagnosis of hepatocellular carcinoma in cirrhotic patients |
publisher |
Egyptian knowledge bank |
series |
International Journal of Medical Arts |
issn |
2636-4174 2682-3780 |
publishDate |
2020-04-01 |
description |
Background: Hepatocellular carcinoma [HCC] is one of the leading causes of cancer-related deaths worldwide. A major problem with HCC surveillance is the lack of reliable biomarkers. Serum transthyretin [TTR] may be a sensitive marker for the diagnosis of patients with liver cell damage, liver cirrhosis or hepatocellular carcinoma. Aim of the work: This study aimed to evaluate the potentiality of serum transthyretin [TTR] as a novel biomarker for detection of HCC in cirrhotic patients. Patients and Methods:This Current study was conducted on 70 patients with chronic liver disease. Also, 20 healthy person matched for age and sex were included as a control group. Patients were classified into 2 groups [30 cirrhotic patients with newly diagnosed HCC & 40 cirrhotic patients without HCC]. Serum TTR levels were measured using enzyme linked immunosorbent assay technique. Results: Serum levels of TTR were significantly much lower in HCC patients when compared to cirrhotic patients without HCC or control group [p<0.0001]. Significant decrease of serum TTR in HCC patients, with portal vein invasion or nodal invasion than in HCC without vascular or nodal invasion. The diagnostic accuracy of TTR was higher than that of AFP regarding sensitivity [83.3%] and negative predictive value [81.4%] in diagnosis of HCC. Conclusion: detection of lower level of TTR alone or in combination with other validated markers may be potentially informative biomarker for detection of HCC among cirrhotic patients at early noninvasive stage where curative treatment can be applied. |
topic |
ttransthyretin cirrhosis hepatocellular carcinoma alpha-fetoprotein noninvasive |
url |
https://ijma.journals.ekb.eg/article_82380_37df342f1483d981733ec70d834c8af1.pdf |
work_keys_str_mv |
AT magdaibrahim transthyretinasanovelbiomarkerfordiagnosisofhepatocellularcarcinomaincirrhoticpatients AT fathiyaelraey transthyretinasanovelbiomarkerfordiagnosisofhepatocellularcarcinomaincirrhoticpatients AT naglaafathy transthyretinasanovelbiomarkerfordiagnosisofhepatocellularcarcinomaincirrhoticpatients AT kadreyelbakrey transthyretinasanovelbiomarkerfordiagnosisofhepatocellularcarcinomaincirrhoticpatients |
_version_ |
1724336606380294144 |